• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    US Stocks Down; Chicago Fed National Activity Index Rises In February

    3/25/24 9:42:15 AM ET
    $ABBV
    $AKAN
    $COOT
    $CYTO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ABBV alert in real time by email

    U.S. stocks traded lower this morning, with the Dow Jones index falling more than 50 points on Monday.

    Following the market opening Monday, the Dow traded down 0.16% to 39,412.36 while the NASDAQ fell 0.42% to 16,359.31. The S&P 500 also fell, dropping, 0.23% to 5,222.33.

    Check This Out: Progress Software Likely To Report Lower Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

     

    Leading and Lagging Sectors

     

    Energy shares jumped by 1.3% on Monday.

    In trading on Monday, information technology shares fell by 0.7%.

     

    Top Headline

     

    The Chicago Fed National Activity Index rose to a three-month high level of 0.05 in February versus a revised reading of -0.54 in the prior month.

     

    Equities Trading UP

     

    Landos Biopharma, Inc. (NASDAQ:LABP) shares shot up 170% to $21.56. AbbVie Inc. (NYSE:ABBV) and Landos Biopharma, reported a definitive agreement under which AbbVie will acquire Landos.

    Shares of Next.e.GO N.V. (NASDAQ:EGOX) got a boost, surging 84% to $0.0724 after falling around 22% on Friday.

    Altamira Therapeutics Ltd. (NASDAQ:CYTO) shares were also up, gaining 85% to $3.1899 after the company announced a collaboration with Univercells Group on nanoparticle-delivered mRNA vaccines.

     

    Equities Trading DOWN

     

    Sintx Technologies, Inc. (NASDAQ:SINT) shares dropped 51% to $0.0450 after the company announced pricing of a $1.3 million public offering of common stock.

    Shares of Akanda Corp. (NASDAQ:AKAN) were down 36% to $0.1569 after the company announced pricing of underwritten public offering.

    Australian Oilseeds Holdings Limited (NASDAQ:COOT) was down, falling 26% to $1.8350 after dipping over 22% on Friday.

    Also Check This Out: Wall Street's Most Accurate Analysts Say Buy These 3 Energy Stocks With Over 5% Dividend Yields

     

    Commodities

     

    In commodity news, oil traded up 0.3% to $80.83 while gold traded up 0.8% at $2,177.10.

    Silver traded up 0.3% to $24.92 on Monday, while copper rose 0.1% to $4.0075.

     

    Euro zone

     

    European shares were mostly lower today. The eurozone’s STOXX 600 fell 0.3%, London’s FTSE 100 fell 0.4% while Spain’s IBEX 35 Index fell 0.2% The German DAX rose 0.1% French CAC 40 fell 0.4% while Italy’s FTSE MIB Index rose 0.4%.

    Spanish industrial producer prices declined by 8.2% year-over-year in February versus a revised 3.9% decline in the prior month.

     

    Asia Pacific Markets

     

    Asian markets closed lower on Monday, with Japan’s Nikkei 225 dipping 1.16%, Hong Kong’s Hang Seng Index falling 0.16% and China’s Shanghai Composite Index falling 0.71%.

    The index of leading economic indicators in Japan was revised lower to 109.5 in January versus a preliminary reading of 109.9, while index of coincident economic indicators was revised higher to 112.1 in January versus the flash reading of 110.2. The annual inflation rate in Malaysia accelerated to 1.8% in February from 1.5% a month ago.

     

    Economics

     

    The Chicago Fed National Activity Index rose to a three-month high level of 0.05 in February versus a revised reading of -0.54 in the prior month.

    Now Read This: Top 2 Real Estate Stocks That May Rocket Higher In March

    Get the next $ABBV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV
    $AKAN
    $COOT
    $CYTO

    CompanyDatePrice TargetRatingAnalyst
    AbbVie Inc.
    $ABBV
    2/20/2026$275.00Overweight
    Barclays
    AbbVie Inc.
    $ABBV
    1/8/2026Outperform → Peer Perform
    Wolfe Research
    AbbVie Inc.
    $ABBV
    1/7/2026$240.00Neutral
    UBS
    AbbVie Inc.
    $ABBV
    12/10/2025$265.00Hold → Buy
    HSBC Securities
    AbbVie Inc.
    $ABBV
    11/13/2025$280.00Sector Outperform
    Scotiabank
    AbbVie Inc.
    $ABBV
    11/4/2025$237.00Buy → Hold
    DZ Bank
    AbbVie Inc.
    $ABBV
    10/14/2025Buy → Hold
    Erste Group
    AbbVie Inc.
    $ABBV
    10/1/2025Buy → Hold
    HSBC Securities
    More analyst ratings

    $ABBV
    $AKAN
    $COOT
    $CYTO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Anderson Mark Lewis bought $9,060 worth of shares (3,000 units at $3.02), increasing direct ownership by 20% to 18,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/19/26 9:00:04 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Investment Officer Honigblum Gregg R. bought $34,896 worth of shares (8,200 units at $4.26), increasing direct ownership by 4% to 201,067 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    12/9/25 8:00:05 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $ABBV
    $AKAN
    $COOT
    $CYTO
    SEC Filings

    View All

    SEC Form 10-K filed by AbbVie Inc.

    10-K - AbbVie Inc. (0001551152) (Filer)

    2/20/26 2:38:42 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SiNtx Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Sintx Technologies, Inc. (0001269026) (Filer)

    2/18/26 8:35:38 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Australian Oilseeds Holdings Limited

    SCHEDULE 13G/A - Australian Oilseeds Holdings Ltd (0001959994) (Subject)

    2/13/26 1:52:48 PM ET
    $COOT
    Packaged Foods
    Consumer Staples

    $ABBV
    $AKAN
    $COOT
    $CYTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, R&D and CSO Thakkar Roopal was granted 18,137 shares, increasing direct ownership by 43% to 60,413 units (SEC Form 4)

    4 - AbbVie Inc. (0001551152) (Issuer)

    2/20/26 6:36:48 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, CHIEF COMMERCIAL OFFICER Stewart Jeffrey Ryan was granted 53,749 shares, increasing direct ownership by 101% to 106,983 units (SEC Form 4)

    4 - AbbVie Inc. (0001551152) (Issuer)

    2/20/26 6:35:24 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, GC AND SECRETARY Siatis Perry C was granted 33,518 shares, increasing direct ownership by 726% to 38,137 units (SEC Form 4)

    4 - AbbVie Inc. (0001551152) (Issuer)

    2/20/26 6:35:21 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AKAN
    $COOT
    $CYTO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

    First all-oral, fixed-duration combination regimen approved for previously untreated patients with CLL Approval supported by data from the Phase 3 AMPLIFY trialRegimen offers another option for the potential of time off treatment, marking a meaningful advance in long-term disease managementNORTH CHICAGO, Ill., Feb. 20, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the combination regimen of VENCLEXTA® (venetoclax) and acalabrutinib for the treatment of previously untreated adult patients with chronic lymphocytic leukemia (CLL). The approval is supported by data from the Phas

    2/20/26 2:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight

    The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others will further propel the market growth.LAS VEGAS, Feb. 19, 2026 /PRNewswire/ -- Recently published Alopecia Areata Market Insights report includes a comprehensive understanding of current treatment practices, alopecia ar

    2/19/26 5:31:00 PM ET
    $ABBV
    $HCWB
    $INCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    AbbVie Declares Quarterly Dividend

    NORTH CHICAGO, Ill., Feb. 19, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.73 per share.  The cash dividend is payable May 15, 2026, to stockholders of record at the close of business on April 15, 2026.Since the company's inception in 2013, AbbVie has increased its dividend by more than 330 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of

    2/19/26 9:37:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AKAN
    $COOT
    $CYTO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    10/18/24 4:38:13 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

    10/17/24 1:29:31 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SKYRIZI issued to ABBVIE INC

    Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-7) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/18/2024. Application Category: BLA, Application Number: 761262, Application Classification:

    6/21/24 4:38:17 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AKAN
    $COOT
    $CYTO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on AbbVie with a new price target

    Barclays initiated coverage of AbbVie with a rating of Overweight and set a new price target of $275.00

    2/20/26 8:23:14 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie downgraded by Wolfe Research

    Wolfe Research downgraded AbbVie from Outperform to Peer Perform

    1/8/26 8:35:39 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS resumed coverage on AbbVie with a new price target

    UBS resumed coverage of AbbVie with a rating of Neutral and set a new price target of $240.00

    1/7/26 9:08:42 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AKAN
    $COOT
    $CYTO
    Financials

    Live finance-specific insights

    View All

    AbbVie Declares Quarterly Dividend

    NORTH CHICAGO, Ill., Feb. 19, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.73 per share.  The cash dividend is payable May 15, 2026, to stockholders of record at the close of business on April 15, 2026.Since the company's inception in 2013, AbbVie has increased its dividend by more than 330 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of

    2/19/26 9:37:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

    Reports Full-Year Diluted EPS of $2.36 on a GAAP Basis, a Decrease of 1.3 Percent; Adjusted Diluted EPS of $10.00, a Decrease of 1.2 Percent; These Results Include an Unfavorable Impact of $2.76 Per Share Related to 2025 Acquired IPR&D and Milestones Expense  Delivers Full-Year Net Revenues of $61.160 Billion, an Increase of 8.6 Percent on a Reported Basis and 8.5 Percent on an Operational Basis  Full-Year Global Net Revenues from the Immunology Portfolio Were $30.406 Billion, an Increase of 14.0 Percent on a Reported Basis, or 13.9 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $17.562 Billion; Global Rinvoq Net Revenues Were $8.304 Billion; Global Humira Net Revenues Wer

    2/4/26 7:48:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call

    NORTH CHICAGO, Ill., Jan. 7, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its full-year and fourth-quarter 2025 financial results on Wednesday, February 4, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key t

    1/7/26 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AKAN
    $COOT
    $CYTO
    Leadership Updates

    Live Leadership Updates

    View All

    SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

    Appointment supports acceleration of revenue opportunities from SiNERGY™ silicon nitride devices and antipathogenic fibrous material technologies SALT LAKE CITY, Utah, Feb. 18, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon nitride (SiN) solutions for medical and other high-value applications, today announced the appointment of Ryan Elmore as President of SINTX Technologies, Inc., effective March 16, 2026. Mr. Elmore most recently served as Core Business Director at Invibio, a division of Victrex plc. With more than 15 years of experience in advanced biomaterials and medical dev

    2/18/26 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Australian Oilseeds Announces Appointment of Amarjeet Singh as Chief Financial Officer

    COOTAMUNDRA, Australia, March 03, 2025 (GLOBE NEWSWIRE) -- Australian Oilseeds Holdings Limited, a Cayman Islands exempted company (the "Company") (NASDAQ:COOT), today announced the appointment of Amarjeet Singh as Chief Financial Officer ("CFO") effective February 28, 2025. Singh brings more than 20 years of finance and accounting experience and held leadership roles at major companies in the global agricultural sector and will replace Bob Wu who is leaving his position to explore new opportunities outside of the Company. "We are excited to welcome Amarjeet as the Company's new Chief Financial Officer," said Gary Seaton, Chief Executive Officer. "His deep expertise in finance and account

    3/3/25 8:00:00 AM ET
    $COOT
    Packaged Foods
    Consumer Staples

    AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors

    Richard A. Gonzalez to retire from the board of directors effective July 1, 2025NORTH CHICAGO, Ill., Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, 2025. He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO and has been chairman since the Company's formation in 2013. "I want to extend my heartfelt gratitude to Rick for his remarkable leadership and dedicated service," said Roxanne S. Austin, lead independent director. "The board and I have complete confidence in Rob, and we are fortunate to

    2/14/25 7:40:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AKAN
    $COOT
    $CYTO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SiNtx Technologies Inc.

    SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

    11/14/24 7:25:52 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Altamira Therapeutics Ltd.

    SC 13G - Altamira Therapeutics Ltd. (0001601936) (Subject)

    11/14/24 3:27:52 PM ET
    $CYTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Australian Oilseeds Holdings Limited

    SC 13G/A - Australian Oilseeds Holdings Ltd (0001959994) (Subject)

    11/12/24 3:48:27 PM ET
    $COOT
    Packaged Foods
    Consumer Staples